Bajaj Finserv ELSS Tax Saver Fund
The scheme seeks to generate long term capital appreciation from a diversified portfolio of predominantly equity and equity related securities while offering deduction on such investment made in the scheme under Section 80C of the Income Tax Act, 1961.
Growthvine rating: 1/5 — ranked #54 of 57 in category.
Fund basics
| Category | Equity: ELSS |
|---|
| NAV | ₹11.71 (as of 2026-08-21) |
|---|
| AUM | ₹89 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nimesh Chandan |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -14.08% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 98.1% of Nifty 500's upside and 104.0% of its downside.
Market cap allocation
| Large cap | 41.7% |
|---|
| Mid cap | 14.5% |
|---|
| Small cap | 43.8% |
|---|
Concentration
| Top 5 holdings | 27.4% |
|---|
| Top 10 holdings | 42.8% |
|---|
| Total holdings | 46 |
|---|
| Index overlap | 24.4% |
|---|
| Active share | 75.6% |
|---|
Top holdings
- ICICI Bank Ltd. — 6.8%
- HDFC Bank Ltd. — 6.3%
- Reliance Industries Ltd — 6.3%
- State Bank Of India — 4.4%
- Zydus Wellness Limited — 3.5%
- Five-Star Business Finance Ltd. — 3.4%
- Clearing Corporation of India Ltd — 3.4%
- Nitin Spinners Ltd. — 3.2%
- Divis Laboratories Ltd. — 3.2%
- PG Electroplast Limited — 3.0%
Top sectors
- Banking & Financial — 21.9%
- Pharma & Biotech — 6.9%
- Finance & Investments — 6.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 2.5% | Q2 | #21 of 52 |